Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...

Investing.com -- Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX) shares surged 30% following the announcement of an exclusive license agreement with Novo Nordisk (NYSE: NVO) for its developmental drug ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for ...

REGIONS NEWS Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments ...

LX9851 is an oral small molecule that blocks Acyl-CoA Synthetase 5 (ACSL5), an enzyme that plays a key role in a metabolic pathway regulating fat accumulation and energy balance. According to ...

A new study suggests early detection improves outcomes, but metabolic episodes in the first days of life still prove challenging.